Decoding 4 Analyst Evaluations For Oscar Health
Portfolio Pulse from Benzinga Insights
Recent analyst evaluations of Oscar Health (NYSE:OSCR) show a mix of opinions, with 3 somewhat bullish and 1 indifferent rating in the last 30 days. The average 12-month price target for OSCR has been raised to $21.25, reflecting a 32.81% increase from the previous target of $16.00. Analysts from Wells Fargo, Goldman Sachs, and Raymond James have adjusted their ratings and price targets, indicating a positive outlook on the company's performance. Oscar Health's financials reveal a strong revenue growth rate of 45.8%, an impressive ROE of 19.32%, and an ROA of 4.42%, despite a net margin below industry averages and a smaller market capitalization.
May 09, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oscar Health's stock may see a positive short-term impact due to recent analyst upgrades and raised price targets, reflecting a bullish sentiment. The company's strong revenue growth and solid financial performance metrics like ROE and ROA support this optimistic outlook, despite challenges in net margin and market capitalization.
The positive short-term impact on OSCR's stock is likely due to the recent analyst upgrades and increased price targets, indicating a bullish sentiment towards the company. The significant improvement in the average price target, supported by strong revenue growth and solid financial performance indicators such as ROE and ROA, suggests a positive outlook. However, the company's below-average net margin and smaller market capitalization are noted challenges that might temper the impact.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100